Ignite Creation Date:
2024-05-05 @ 11:25 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00034697
Status:
TERMINATED
Last Update Posted:
2017-05-23
First Post:
2002-05-01
Brief Title:
Study of Temozolomide in the Treatment of Brain Metastasis From Non-small-cell Lung Cancer Study P02143
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Study Overview
Official Title:
A Phase II Study of Temozolomide SCH 52365 in Subjects With Brain Metastasis From Non-Small-Cell Lung Cancer
Status:
TERMINATED
Status Verified Date:
2017-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Slow Enrollment
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Brain metastases from solid tumors are diagnosed in more than 300000 patients annually Nonsmall cell lung cancer accounts for the majority of CNS mets Treatment with whole brain radiation and steroids will improve neurologic symptoms in about 50 of patients although survival is short This study will test the safety and efficacy of temozolomide in combination with radiation therapy in the treatment of patients with brain mets form nonsmall cell lung cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None